Xiaoyan Michelle Zhang - Jan 10, 2022 Form 4 Insider Report for Ikena Oncology, Inc. (IKNA)

Role
Chief Scientific Officer
Signature
/s/ Douglas R. Carlson, as Attorney-in-Fact for Xiaoyan Michelle Zhang
Stock symbol
IKNA
Transactions as of
Jan 10, 2022
Transactions value $
-$9,854
Form type
4
Date filed
1/12/2022, 06:25 PM
Previous filing
Dec 14, 2021
Next filing
Feb 4, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IKNA Common Stock Options Exercise $77.30 +36 +0.08% $2.15 44.5K Jan 10, 2022 Direct
transaction IKNA Common Stock Sale -$432 -36 -0.08% $12.00 44.5K Jan 10, 2022 Direct F1
transaction IKNA Common Stock Options Exercise $2.07K +964 +2.17% $2.15 45.4K Jan 11, 2022 Direct
transaction IKNA Common Stock Sale -$11.6K -964 -2.12% $12.00 44.5K Jan 11, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKNA Stock Option (Right to Buy) Options Exercise $0 -36 -0.14% $0.00 25.4K Jan 10, 2022 Common Stock 36 $2.15 Direct F2
transaction IKNA Stock Option (Right to Buy) Options Exercise $0 -964 -3.79% $0.00 24.5K Jan 11, 2022 Common Stock 964 $2.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2021.
F2 25% of the shares subject to this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter.